Related Experiment Videos
The effect of lovastatin on [3H]thymidine uptake in HTC-4 and LLC-L1 tumor cells
T J Morris1, S L Palm, L T Furcht
1Department of Surgery, University of Minnesota Medical School, Minneapolis 55455, USA.
Abstract:
Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, has been shown to inhibit the in vitro and in vivo growth of a number of different cell lines. However, the mechanism by which lovastatin exerts its effect is not clear. In this experiment, we investigated the effect of lovastatin on the incorporation of [3H]thymidine by Hepatoma Tissue Culture-4 (HTC-4) and Lewis Lung Carcinoma L-1 (LLC-L1) tumor cells. Tumor cells were grown under standard conditions and treated with four different concentrations of lovastatin. Cell growth was evaluated by daily hemacytometer cell counts. On Day 4, the plates were pulsed with 10 microCi [3H]thymidine. After 24 hr, the plates were harvested and [3H]thymidine incorporation was measured by scintillation counting. Lovastatin inhibited both HTC-4 and LLC-L1 cell growth in a dose-dependent manner. At the highest lovastatin dose, both LLC-L1 and HTC-4 cell growth was slowed to less than 15% of control. Remarkably, however, both cell lines showed a paradoxical, dose related, increase in [3H]thymidine uptake. Cell cycle analysis using flow cytometry was performed on Day 5 in the LLC-L1 cell line. As the lovastatin concentration increased, a lower percentage of cells was found in the G1 phase of the cell cycle and a higher percentage of cells was found in the S and G2 phases. These findings suggest that these tumor cells are undergoing brisk DNA repair or that lovastatin is more effectively blocking cell division than cellular DNA replication.
Insights
Lovastatin inhibits tumor cell growth, but paradoxically increases DNA replication markers. This suggests lovastatin may promote DNA repair or block cell division more than replication in cancer cells.
Area of Science:
- Biochemistry
- Cell Biology
- Pharmacology
Background:
- Lovastatin is a HMG-CoA reductase inhibitor with known anti-cancer properties.
- The precise mechanism of lovastatin's anti-proliferative effect on tumor cells remains unclear.
- This study investigates lovastatin's impact on DNA synthesis and cell cycle progression in specific cancer cell lines.
Purpose of the Study:
- To determine the effect of lovastatin on tumor cell growth and [3H]thymidine incorporation.
- To elucidate the mechanism behind lovastatin's observed effects on cell proliferation and DNA synthesis.
- To analyze the cell cycle distribution of tumor cells treated with lovastatin.
Main Methods:
- Hepatoma Tissue Culture-4 (HTC-4) and Lewis Lung Carcinoma L-1 (LLC-L1) cells were treated with varying concentrations of lovastatin.
- Cell growth was monitored via daily hemacytometer counts.
- [3H]thymidine incorporation was measured using scintillation counting, and cell cycle analysis was performed using flow cytometry.
Main Results:
- Lovastatin demonstrated a dose-dependent inhibition of both HTC-4 and LLC-L1 cell growth.
- A paradoxical, dose-related increase in [3H]thymidine uptake was observed in both cell lines.
- Flow cytometry revealed a decrease in G1 phase and an increase in S and G2 phases with increasing lovastatin concentration.
Conclusions:
- Lovastatin effectively inhibits tumor cell proliferation in a dose-dependent manner.
- The increased [3H]thymidine uptake suggests enhanced DNA repair or a dissociation between DNA replication and cell division.
- Lovastatin may preferentially impede cell division over DNA replication in these tumor cells.